Insuficiência Renal Crónica – Casuística de 16 Anos (1986-2001) da Unidade de Nefrologia do Hospital de Dona Estefânia

Entre Janeiro 1986 e Dezembro de 2001 foram seguidos na nossa Unidade 100 doentes com Insuficiência Renal Crónica com idade igual ou inferior a 15 anos (M:F = 54:46; idade ≥ 0 ≤15 anos). A idade de detecção da doença foi inferior aos dois anos em 35% dos casos. Cinquenta e nove doentes (59%) atingiram a fase de Insuficiência Renal Terminal no decurso destes 16 anos, tendo sido transplantados 41 (69,5%), encontrando-se no final do estudo 12 (20,3%) doentes em hemodiálise, três (5,1%) em diálise peritoneal e um em preparação para indução de diálise peritoneal. Registaram-se cinco óbitos, dois dos quais ocorreram após transplantação renal. Durante o período em estudo a hemodiálise foi a primeira forma de terapêutica de substituição da função renal em 33 casos (55,9%) dos doentes que atingiram a insuficiência renal terminal. Contudo a diálise peritoneal, instituida em 24 doentes (42,1%) foi a primeira escolha em 10 ( 100%) das crianças com menos de seis anos , submetidas a terapêutica de substituição da função renal. Dos 41 doentes transplantados registaramse dois óbitos e oito rejeições, com necessidade de instituição de hemodiálise em dois casos, de diálise peritoneal noutro e de duas retransplantações.

Hydrops Fetalis - Revisão de 16 Casos

Os autores fizeram um estudo retrospectivo de 16 casos de hydrops fetalis observados durante um período de 4 anos na Maternidade Dr. Alfredo da Costa. Em 5 dos recém-nascidos (RN) a hydrops era devida a isoimunização Rh. Nos 11 casos de natureza não imune, uma causa ou a presença de anomalias associadas foram detectadas em 4 doentes: taquicardia supraventricular (2 casos), doença renal multiquística (1 caso) e mielomeningocelo (1 caso). Os restantes casos eram de origem idiopática. Dois doentes faleceram in útero e quatro no período neonatal – mortalidade perinatal de 37%. A mortalidade foi mais elevada nos RN com idade gestacional mais baixa, no grupo com hydrops não imune, e nos RN com complicações orgânicas ou metabólicas graves. São revistos os problemas clínicos mais frequentes nesta situação, em particular o diagnóstico e actuação pré-natal, a asfixia perinatal e as complicações no período neonatal.

Amniocentesis in HIV Pregnant Women: 16 Years of Experience

The iatrogenic risk of HIV vertical transmission, calculated in initial epidemiologic studies, seemed to counterindicate invasive prenatal diagnosis (PND) procedures. The implementation of highly active antiretroviral therapy (HAART) represented a turning point in PND management, owing to a rapid and effective reduction of maternal viral load (VL). In the present study, we identified cases of vertical transmission in HIV-infected pregnant women who did amniocentesis in the second trimester of pregnancy (n = 27), from 1996 to 2011. We divided our sample into Group A--women under HAART when submitted to amniocentesis (n = 20) and Group B--women without antiretroviral therapy before amniocentesis (n = 7). We had 1 case of vertical transmission in Group B. Preconceptional or early first trimester HIV serology is essential to avoid performing an amniocentesis without antiretroviral therapy or viral suppression. When there is an indication for amniocentesis in an HIV-infected pregnant woman, it should be done if the patient is on HAART and, if possible, when VL is undetectable. Nowadays, with combined first trimester screening test to select pregnancies with high risk of aneuploidies, advanced maternal age is a less frequent indication to perform PND invasive procedures, representing an outstanding gain in prenatal diagnosis of this population.

The PROP1 2-Base Pair Deletion Is a Common Cause of Combined Pituitary Hormone Deficiency

Combined pituitary hormone deficiency (CPHD) has an incidence of approximately 1 in 8000 births. Although the proportion of familial CPHD cases is unknown, about 10% have an affected first degree relative. We have recently reported three mutations in the PROP1 gene that cause CPHD in human subjects. We report here the frequency of one of these mutations, a 301–302delAG deletion in exon 2 of PROP1, in 10 independently ascertained CPHD kindreds and 21 sporadic cases of CPHD from 8 different countries. Our results show that 55% (11 of 20) of PROP1 alleles have the 301–302delAG deletion in familial CPHD cases. Interestingly, although only 12% (5 of 42) of the PROP1 alleles of our 21 sporadic cases were 301–302delAG, the frequency of this allele (in 20 of 21 of the sporadic subjects given TRH stimulation tests) was 50% (3 of 6) and 0% (0 of 34) in the CPHD cases with pituitary and hypothalamic defects, respectively. Using whole genome radiation hybrid analysis, we localized the PROP1 gene to the distal end of chromosome 5q and identified a tightly linked polymorphic marker, D5S408, which can be used in segregation studies. Analysis of this marker in affected subjects with the 301–302delAG deletion suggests that rather than being inherited from a common founder, the 301–302delAG may be a recurring mutation.

The PROP1 2-Base Pair Deletion Is a Common Cause of Combined Pituitary Hormone Deficiency

Combined pituitary hormone deficiency (CPHD) has an incidence of approximately 1 in 8000 births. Although the proportion of familial CPHD cases is unknown, about 10% have an affected first degree relative. We have recently reported three mutations in the PROP1 gene that cause CPHD in human subjects. We report here the frequency of one of these mutations, a 301-302delAG deletion in exon 2 of PROP1, in 10 independently ascertained CPHD kindreds and 21 sporadic cases of CPHD from 8 different countries. Our results show that 55% (11 of 20) of PROP1 alleles have the 301-302delAG deletion in familial CPHD cases. Interestingly, although only 12% (5 of 42) of the PROP1 alleles of our 21 sporadic cases were 301-302delAG, the frequency of this allele (in 20 of 21 of the sporadic subjects given TRH stimulation tests) was 50% (3 of 6) and 0% (0 of 34) in the CPHD cases with pituitary and hypothalamic defects, respectively. Using whole genome radiation hybrid analysis, we localized the PROP1 gene to the distal end of chromosome 5q and identified a tightly linked polymorphic marker, D5S408, which can be used in segregation studies. Analysis of this marker in affected subjects with the 301-302delAG deletion suggests that rather than being inherited from a common founder, the 301-302delAG may be a recurring mutation.